Patents by Inventor Yoshimasa Inagaki
Yoshimasa Inagaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10550181Abstract: Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: GrantFiled: December 9, 2016Date of Patent: February 4, 2020Assignees: KYOWA KIRIN CO., LTD, Kyushu University, National University CorporationInventors: Shin-ichiro Takayanagi, Hitomi Tomura, Tomonori Tawara, Yoshimasa Inagaki, Tsuguo Kubota, Koichi Akashi, Yoshikane Kikushige
-
Patent number: 9958446Abstract: Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(?)CD34(+)CD38(?) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).Type: GrantFiled: August 29, 2016Date of Patent: May 1, 2018Assignees: KYOWA HAKKO KIRIN CO., LTD, Kyushu University, National University CorporationInventors: Shinichiro Takayanagi, Yoshimasa Inagaki, Koichi Akashi, Yoshikane Kikushige
-
Publication number: 20170088616Abstract: Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: ApplicationFiled: December 9, 2016Publication date: March 30, 2017Applicants: KYOWA HAKKO KIRIN CO., LTD, KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Shin-ichiro TAKAYANAGI, Hitomi TOMURA, Tomonori TAWARA, Yoshimasa INAGAKI, Tsuguo KUBOTA, Koichi AKASHI, Yoshikane KIKUSHIGE
-
Patent number: 9556270Abstract: Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: GrantFiled: September 5, 2013Date of Patent: January 31, 2017Assignees: KYOWA HAKKO KIRIN CO., LTD, KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Shin-ichiro Takayanagi, Hitomi Tomura, Tomonori Tawara, Yoshimasa Inagaki, Tsuguo Kubota, Koichi Akashi, Yoshikane Kikushige
-
Patent number: 9540441Abstract: The present invention provides an antibody to human IL-3R? chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R? chain but does not bind to C domain of the human IL-3R? chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R? as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R? antibody as an active ingredient.Type: GrantFiled: June 15, 2016Date of Patent: January 10, 2017Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Tomonori Tawara, Shinichiro Takayanagi, Yoshimasa Inagaki
-
Publication number: 20160363595Abstract: Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(?)CD34(+)CD38(?) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).Type: ApplicationFiled: August 29, 2016Publication date: December 15, 2016Applicants: KYOWA HAKKO KIRIN CO., LTD, Kyushu University, National University CorporationInventors: Shinichiro TAKAYANAGI, Yoshimasa INAGAKI, Koichi AKASHI, Yoshikane KIKUSHIGE
-
Patent number: 9487591Abstract: Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(?)CD34(+)CD38(?) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).Type: GrantFiled: June 15, 2015Date of Patent: November 8, 2016Assignees: KYOWA HAKKO KIRIN CO., LTD, Kyushu University, National University CorporationInventors: Shinichiro Takayanagi, Yoshimasa Inagaki, Koichi Akashi, Yoshikane Kikushige
-
Publication number: 20160280792Abstract: The present invention provides an antibody to human IL-3R? chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R? chain but does not bind to C domain of the human IL-3R? chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R? as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R? antibody as an active ingredient.Type: ApplicationFiled: June 15, 2016Publication date: September 29, 2016Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Tomonori TAWARA, Shinichiro TAKAYANAGI, Yoshimasa INAGAKI
-
Patent number: 9394370Abstract: The present invention provides an antibody to human IL-3R? chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R? chain but does not bind to C domain of the human IL-3R? chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R? as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R? antibody as an active ingredient.Type: GrantFiled: June 7, 2013Date of Patent: July 19, 2016Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Tomonori Tawara, Shinichiro Takayanagi, Yoshimasa Inagaki
-
Publication number: 20150284468Abstract: Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(?)CD34(+)CD38(?) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).Type: ApplicationFiled: June 15, 2015Publication date: October 8, 2015Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, KYOWA HAKKO KIRIN CO., LTDInventors: Shinichiro TAKAYANAGI, Yoshimasa INAGAKI, Koichi AKASHI, Yoshikane KIKUSHIGE
-
Patent number: 9103832Abstract: Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(?)CD34(+)CD38(?) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).Type: GrantFiled: December 20, 2013Date of Patent: August 11, 2015Assignees: KYOWA HAKKO KIRIN CO., LTD., Kyushu University, National University CorporationInventors: Shinichiro Takayanagi, Yoshimasa Inagaki, Koichi Akashi, Yoshikane Kikushige
-
Publication number: 20140134639Abstract: Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(?)CD34(+)CD38(?) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).Type: ApplicationFiled: December 20, 2013Publication date: May 15, 2014Applicants: Kyushu University, National University Corporation, KYOWA HAKKO KIRIN CO., LTDInventors: Shinichiro TAKAYANAGI, Yoshimasa INAGAKI, Koichi AKASHI, Yoshikane KIKUSHIGE
-
Publication number: 20140044728Abstract: Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: ApplicationFiled: September 5, 2013Publication date: February 13, 2014Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, KYOWA HAKKO KIRIN CO., LTDInventors: Shin-ichiro TAKAYANAGI, Hitomi TOMURA, Tomonori TAWARA, Yoshimasa INAGAKI, Tsuguo KUBOTA, Koichi AKASHI, Yoshikane KIKUSHIGE
-
Patent number: 8647623Abstract: Disclosed is a therapeutic method comprising administering a TIM-3 antibody to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(?)CD34(+)CD38(?) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Also disclosed is a composition for preventing or treating blood tumor, which comprises a TIM-3 antibody as an active ingredient. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)), all of which are capable of expressing TIM-3.Type: GrantFiled: April 9, 2010Date of Patent: February 11, 2014Assignees: Kyowa Hakko Kirin Co., Ltd, Kyushu University, National University CorporationInventors: Shinichiro Takayanagi, Yoshimasa Inagaki, Koichi Akashi, Yoshikane Kikushige
-
Publication number: 20130295107Abstract: The present invention provides an antibody to human IL-3R? chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R? chain but does not bind to C domain of the human IL-3R? chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R? as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R? antibody as an active ingredient.Type: ApplicationFiled: June 7, 2013Publication date: November 7, 2013Inventors: Tomonori Tawara, Shinichiro Takayanagi, Yoshimasa Inagaki
-
Patent number: 8552156Abstract: The present invention provides an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: GrantFiled: June 13, 2011Date of Patent: October 8, 2013Assignees: Kyowa Hakko Kirin Co., Ltd, Kyushu University, National University CorporationInventors: Shin-ichiro Takayanagi, Hitomi Tomura, Tomonori Tawara, Yoshimasa Inagaki, Tsuguo Kubota, Koichi Akashi, Yoshikane Kikushige
-
Patent number: 8492119Abstract: The present invention provides an antibody to human IL-3R? chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R? chain but does not bind to C domain of the human IL-3R? chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R? as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R? antibody as an active ingredient.Type: GrantFiled: April 27, 2010Date of Patent: July 23, 2013Assignee: Kyowa Hakko Kirin Co., LtdInventors: Tomonori Tawara, Shinichiro Takayanagi, Yoshimasa Inagaki
-
Publication number: 20120189617Abstract: The present invention provides an anti-human TIM-3 antibody which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure thereof and exhibits higher effector activity such as an antibody-dependent cellular cytotoxicity (ADCC activity) for diseases relating to a human TIM-3 expressing cell. The present invention provides a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: ApplicationFiled: June 13, 2011Publication date: July 26, 2012Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, KYOWA HAKKO KIRIN CO., LTDInventors: Shin-ichiro TAKAYANAGI, Hitomi TOMURA, Tomonori TAWARA, Yoshimasa INAGAKI, Tsuguo KUBOTA, Koichi AKASHI, Yoshikane KIKUSHIGE
-
Publication number: 20120100131Abstract: Disclosed is a therapeutic method comprising administering a TIM-3 antibody to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(?)CD34(+)CD38(?) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Also disclosed is a composition for preventing or treating blood tumor, which comprises a TIM-3 antibody as an active ingredient. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)), all of which are capable of expressing TIM-3.Type: ApplicationFiled: April 9, 2010Publication date: April 26, 2012Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORP., KYOWA HAKKO KIRIN CO., LTDInventors: Shinichiro Takayanagi, Yoshimasa Inagaki, Koichi Akashi, Yoshikane Kikushige
-
Publication number: 20120070448Abstract: The present invention provides an antibody to human IL-3R? chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R? chain but does not bind to C domain of the human IL-3R? chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R? as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R? antibody as an active ingredient.Type: ApplicationFiled: April 27, 2010Publication date: March 22, 2012Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Tomonori Tawara, Shinichiro Takayanagi, Yoshimasa Inagaki